The ability to predict which oral precancer will eventuate to cancer will reduce the mortality and morbidity of this dreadful cancer which accounts for 38,000 new cancer cases in the United States and 350,000 worldwide. Only 20% of oral precancers progress to cancer and currently there is no clinical, morphological nor molecular parameter that can predict the malignant progression of oral precancers. This proposal aims to harness the molecular determinants of oral precancer progression using genomic, transcriptional and proteomic approaches on patient population that will permit the maximal utility of emerging technologies to address this critical research and biological question in head and neck cancer. The hypothesis to be tested is that oral precancer that eventuates to cancer harbor genomic, transcriptional and proteomic alterations which serves to advance the pathogenesis as well as valuable biomarkers of this disease. Patient resources are in place to permit genomic, transcriptional and proteomic studies including longitudinal cohorts of oral precancer patients with clinical outcome (Aim 1). Bioinformatics and biocomputational expertise are in place to harness diagnostic molecular determinants in the progressing oral precancers and to build Prediction Models for Oral Precancer Progression (PMOPP) (Aim 2). Submodels to use saliva and serum as a diagnostic fluid for oral cancer detection will also be generated.
Aim 3 is to test the predictor models in a multi-center setting to evaluate the clinical utility of the oral precancer prediction models. We envision to generate a non-invasive prediction model, based on saliva and/or serum, for the early detection of progressing oral precancer. This proposal optimally utilize existing patient resources and emerging genomic, transcriptional and Proteomic tools to harness genomic, transcriptional and proteomic determinants in oral precancer progression. The outcome of the validated molecular determinants will be utilized for biological mechanistic studies as well as translational research applications, directions that are well in place in our laboratories. ? ?
| Nonaka, Taichiro; Wong, David T W (2017) Saliva-Exosomics in Cancer: Molecular Characterization of Cancer-Derived Exosomes in Saliva. Enzymes 42:125-151 |
| Yang, Jieping; Wei, Fang; Schafer, Christopher et al. (2014) Detection of tumor cell-specific mRNA and protein in exosome-like microvesicles from blood and saliva. PLoS One 9:e110641 |
| Kim, Jeong Kyu; Zhou, Hui; Nabili, Vishad et al. (2013) Utility of multiple sampling in reducing variation of salivary interleukin-8 and interleukin-1? mRNA levels in healthy adults. Head Neck 35:968-73 |
| Baum, B J; Yates 3rd, J R; Srivastava, S et al. (2011) Scientific frontiers: emerging technologies for salivary diagnostics. Adv Dent Res 23:360-8 |
| Hu, Shen; Arellano, Martha; Boontheung, Pinmanee et al. (2008) Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 14:6246-52 |
| Deshpande, Amit M; Wong, David T (2008) Molecular mechanisms of head and neck cancer. Expert Rev Anticancer Ther 8:799-809 |
| Brooks, Mai N; Wang, Jianghua; Li, Yang et al. (2008) Salivary protein factors are elevated in breast cancer patients. Mol Med Report 1:375-378 |
| Hu, Zhanzhi; Zimmermann, Bernhard G; Zhou, Hui et al. (2008) Exon-level expression profiling: a comprehensive transcriptome analysis of oral fluids. Clin Chem 54:824-32 |
| Ye, Hui; Yu, Tianwei; Temam, Stephane et al. (2008) Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics 9:69 |
| Zimmermann, Bernhard G; Wong, David T (2008) Salivary mRNA targets for cancer diagnostics. Oral Oncol 44:425-9 |
Showing the most recent 10 out of 27 publications
